Evidence map›Paper›PMID 36451879›Full record

ArticlemedRxiv : the preprint server for health sciences2022

SARS-CoV-2 evolves increased infection elicited cell death and fusion in an immunosuppressed individual.

Gila Lustig, Yashica Ganga, Hylton Rodel, Houriiyah Tegally, Laurelle Jackson, Sandile Cele, Khadija Khan, Zesuliwe Jule, Kajal Reedoy, Farina Karim and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Gila LustigCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Yashica GangaAfrica Health Research Institute, Durban, South Africa.
Hylton RodelCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Houriiyah TegallyKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Laurelle JacksonAfrica Health Research Institute, Durban, South Africa.
Sandile CeleAfrica Health Research Institute, Durban, South Africa.
Khadija KhanAfrica Health Research Institute, Durban, South Africa.
Zesuliwe JuleAfrica Health Research Institute, Durban, South Africa.
Kajal ReedoyAfrica Health Research Institute, Durban, South Africa.
Farina KarimAfrica Health Research Institute, Durban, South Africa.
Mallory BernsteinAfrica Health Research Institute, Durban, South Africa.
Mahomed-Yunus S MoosaDepartment of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
Derseree ArcharyCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Tulio de OliveiraKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Richard LessellsKwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
Salim S Abdool KarimCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Alex SigalCentre for the AIDS Programme of Research in South Africa, Durban, South Africa.
Africa Health Research Institute · ZACentre for the AIDS Programme of Research in South Africa · ZAUniversity of KwaZulu-Natal · ZAUniversity of Washington · US

Funding

Identification of the HIV Reservoir in Lymph Nodes Using Single Cell RNA-SeqR01AI138546 · NIAID · KWAZULU-NATAL RESEARCH INSTITUTE TB-HIV · PI SIGAL, ALEXANDER · 2018 to 2022
$721k
NIAID NIH HHS R01 AI138546
6 · The paper itself

Abstract

The milder clinical manifestations of Omicron infection relative to pre-Omicron SARS CoV-2 raises the possibility that extensive evolution results in reduced pathogenicity. To test this hypothesis, we quantified induction of cell fusion and cell death in SARS CoV-2 evolved from ancestral virus during long-term infection. Both cell fusion and death were reduced in Omicron BA.1 infection relative to ancestral virus. Evolved virus was isolated at different times during a 6-month infection in an immunosuppressed individual with advanced HIV disease. The virus isolated 16 days post-reported symptom onset induced fusogenicity and cell death at levels similar to BA.1. However, fusogenicity was increased in virus isolated at 6 months post-symptoms to levels intermediate between BA.1 and ancestral SARS-CoV-2. Similarly, infected cell death showed a graded increase from earlier to later isolates. These results may indicate that, at least by the cellular measures used here, evolution in long-term infection does not necessarily attenuate the virus.

Identifiers

PMID36451879
PMCPMC9709797
OpenAlexW4309988503

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.